SHH pathway is also extensively implicated in other malignancies, including estrogen receptor (ER+)-positive and triple-negative breast cancer (TNBC), for which overall survival and disease-free survival are 62% and 57%, respectively [13,14,15,16]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.